The Focal Segmental Glomerulosclerosis market report also offers comprehensive insights into the Focal Segmental Glomerulosclerosis market size, share, Focal Segmental Glomerulosclerosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Focal Segmental Glomerulosclerosis market size growth forward.
Some of the key highlights from the Focal Segmental Glomerulosclerosis Market Insights Report:
Several key pharmaceutical companies, including Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company, and others, are developing novel products to improve the Focal Segmental Glomerulosclerosis treatment outlook.
The Focal Segmental Glomerulosclerosis market was valued at around USD 734 million in 2022 and is expected to expand at a substantial compound annual growth rate (CAGR) throughout the forecast period (2020-2034).
In March 2024, ZyVersa Therapeutics achieved a major milestone by launching its first-in-human clinical trial for VAR 200. The trial is designed to confirm the promising preclinical results seen in three different animal models of kidney disease, including diabetic kidney disease, focal segmental glomerulosclerosis, and Alport syndrome, and assess their relevance for patients with kidney disease.
In 2022, the United States accounted for around 34% of the total Focal Segmental Glomerulosclerosis (FSGS) drug market, with significant growth expected during the forecast period.
The combined market of the EU4 and the UK reached an estimated USD 147 million in 2022, and is projected to grow at a strong compound annual growth rate (CAGR). Within Europe, France held the largest market share in 2022, followed by Germany.
The Focal Segmental Glomerulosclerosis (FSGS) market is expected to experience growth throughout the forecast period (2023–2034), driven by the approval of promising new drugs.
According to DelveInsight’s analysis, the United States accounts for the highest proportion of diagnosed FSGS cases, representing 46.96% of the total in the 7MM. Japan follows with approximately 14.83% of diagnosed FSGS cases in 2022. Our analysis suggests that men are more commonly affected by FSGS across the 7MM, a disparity potentially influenced by factors such as hormones, genetics, and environment. The FSGS market in the 7MM is largely driven by therapies like Statins, Ezetimibe/Bempedoic Acid and their combinations, along with PCSK9 inhibitors, which collectively generated nearly USD 23 million in 2022.
As per DelveInsight analysis, the Focal Segmental Glomerulosclerosis market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Focal Segmental Glomerulosclerosis Market Landscape
Focal Segmental Glomerulosclerosis Overview
Focal Segmental Glomerulosclerosis (FSGS) is a kidney disorder characterized by scarring (sclerosis) in specific segments (focal) of the glomeruli, the kidney’s filtering units. The glomeruli play a crucial role in producing urine by filtering waste and excess fluid from the blood. Symptoms of FSGS include proteinuria (large amounts of protein in the urine), edema (swelling, particularly around the eyes, hands, feet, and abdomen, which leads to sudden weight gain), low blood albumin levels, high cholesterol in some cases, high blood pressure, and an increased tendency to develop blood clots.
Do you know the treatment paradigms for different countries? Download our Focal Segmental Glomerulosclerosis Market Sample Report
Focal Segmental Glomerulosclerosis Epidemiology Segmentation
DelveInsight’s Focal Segmental Glomerulosclerosis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Focal Segmental Glomerulosclerosis historical patient pools and forecasted Focal Segmental Glomerulosclerosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Focal Segmental Glomerulosclerosis Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Focal Segmental Glomerulosclerosis Prevalence
Age-Specific Focal Segmental Glomerulosclerosis Prevalence
Gender-Specific Focal Segmental Glomerulosclerosis Prevalence
Diagnosed and Treatable Cases of Focal Segmental Glomerulosclerosis
Visit for more @ Focal Segmental Glomerulosclerosis Epidemiological Insights
Focal Segmental Glomerulosclerosis Market Outlook
Focal Segmental Glomerulosclerosis (FSGS) includes a range of conditions such as coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease, all of which are linked to atherosclerosis. FSGS is shaped by genetic factors, lifestyle choices, and existing comorbidities. Treatment approaches vary based on the severity of the condition, with the goal of managing FSGS. Initial treatment focuses on lifestyle changes, including stress management, regular exercise, a balanced diet, and smoking cessation. A comprehensive review of their impact on patient outcomes emphasizes how these changes can complement pharmaceutical treatments and effectively reduce cardiovascular risk factors.
Focal Segmental Glomerulosclerosis Marketed Drugs
LEQVIO (Inclisiran): Novartis Pharmaceuticals Corporation
Focal Segmental Glomerulosclerosis Emerging Drugs
Olpasiran (AMG 890): Amgen Inc.
Focal Segmental Glomerulosclerosis Key Companies
Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company, and others
For more information, visit Focal Segmental Glomerulosclerosis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Focal Segmental Glomerulosclerosis Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Focal Segmental Glomerulosclerosis, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Focal Segmental Glomerulosclerosis epidemiology in the 7MM
Focal Segmental Glomerulosclerosis marketed and emerging therapies
Focal Segmental Glomerulosclerosis companies
Focal Segmental Glomerulosclerosis market drivers and barriers
Table of Contents:
1 Focal Segmental Glomerulosclerosis Market Key Comprehensive Insights
2 Focal Segmental Glomerulosclerosis Market Report Introduction
3 Competitive Intelligence Analysis for Focal Segmental Glomerulosclerosis
4 Focal Segmental Glomerulosclerosis Market Analysis Overview at a Glance
5 Executive Summary of Focal Segmental Glomerulosclerosis
6 Focal Segmental Glomerulosclerosis Epidemiology and Market Methodology
7 Focal Segmental Glomerulosclerosis Epidemiology and Patient Population
8 Focal Segmental Glomerulosclerosis Patient Journey
9 Focal Segmental Glomerulosclerosis Treatment Algorithm, Focal Segmental Glomerulosclerosis Current Treatment, and Medical Practices
10 Key Endpoints in Focal Segmental Glomerulosclerosis Clinical Trials
11 Focal Segmental Glomerulosclerosis Marketed Therapies
12 Focal Segmental Glomerulosclerosis Emerging Therapies
13 Focal Segmental Glomerulosclerosis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Focal Segmental Glomerulosclerosis
16 Focal Segmental Glomerulosclerosis Market Key Opinion Leaders Reviews
18 Focal Segmental Glomerulosclerosis Market Drivers
19 Focal Segmental Glomerulosclerosis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Focal Segmental Glomerulosclerosis Epidemiology 2034
DelveInsight’s “Focal Segmental Glomerulosclerosis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Focal Segmental Glomerulosclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Focal Segmental Glomerulosclerosis Pipeline 2024
“Focal Segmental Glomerulosclerosis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Focal Segmental Glomerulosclerosis market. A detailed picture of the Focal Segmental Glomerulosclerosis pipeline landscape is provided, which includes the disease overview and Focal Segmental Glomerulosclerosis treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
